Oncology Experts Discuss On-Body Subcutaneous Isatuximab in Multiple Myeloma

Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, of Cleveland Clinic, and Sikander Ailawadhi, MD, of Mayo Clinic, examine the transition toward automated on-body administration for multiple myeloma treatments. The discussion followed the U.S. Food and Drug Administration (FDA) approval of subcutaneous isatuximab-irfc (Sarclisa Escena) administered via the CirCLIQ on-body delivery system (OBDS) across all approved multiple myeloma indications.